Fundz

Who to call at DiaMedica Therapeutics, and when

Fundz watches for the moments DiaMedica Therapeutics starts buying, and tells you who to reach.

  • An alert the day DiaMedica Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at DiaMedica Therapeutics, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

LaunchDiaMedica Therapeutics Inc. announces the dosing of the first patient in a Phase 2 trial of DM199 aimed at treating preeclampsia.

Nov 13, 2024
MinneapolisBiotechnologyHealth CareTherapeuticsBiopharma

Product Description

DiaMedica Therapeutics has announced that the first patient has been dosed in their Phase 2 trial of DM199, designed to treat preeclampsia. This milestone is anticipated to lead to significant insights regarding the safety and efficacy of DM199 in addressing this serious pregnancy disorder.

Company Information

Company

DiaMedica Therapeutics

Location

301 CARLSON PARKWAY

Minneapolis, Minnesota, United States

About

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), is a clinical-stage biopharmaceutical company that is focused on developing novel treatments where there is significant unmet clinical need or where no current therapies are available, with the focus on acute ischemic stroke and preeclampsia.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment DiaMedica Therapeutics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Dominic hidden

hidden
hidden
Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for DiaMedica Therapeutics's next move

Learn about Strategic plan

Product Launch Insights

What this usually means
Market expansion signals
New product launches often coincide with market expansion initiatives

DiaMedica Therapeutics shipped something new. Fundz reads product launches, trademark filings and hiring together.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.